Related Experiment Video
Updated: Jun 14, 2025
07:51
A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder
Published on: June 18, 2018
10.5K
Synaptogyrin-3 Prevents Cocaine Addiction and Dopamine Deficits
Biorxiv : the Preprint Server for Biology
|August 30, 2024
Summary
Synaptogyrin-3, a synaptic protein, is reduced by chronic cocaine use. Increasing its levels may help treat cocaine use disorder by improving dopamine signaling and reducing drug-seeking behaviors.
Area of Science:
- Neuroscience
- Molecular Biology
- Pharmacology
Background:
- Synaptogyrin-3 is a poorly understood protein found in synaptic vesicles.
- It interacts with dopamine transporters, influencing dopamine release and reuptake.
- Chronic cocaine exposure reduces synaptogyrin-3 levels in humans and rats.
Purpose of the Study:
- To investigate the role of synaptogyrin-3 in cocaine use disorder.
- To explore the therapeutic potential of synaptogyrin-3 in modulating dopamine signaling and cocaine-related behaviors.
Main Methods:
- Assessed synaptogyrin-3 levels in human and rat models of chronic cocaine exposure.
- Examined the correlation between synaptogyrin-3 levels and cocaine motivation in rats.
- Utilized overexpression of synaptogyrin-3 in dopamine neurons to evaluate its effects on cocaine self-administration, anxiety, and cognitive flexibility.
- Measured dopamine signaling in the nucleus accumbens.
Main Results:
- Synaptogyrin-3 levels were decreased following chronic cocaine exposure.
- Lower synaptogyrin-3 levels correlated with increased motivation for cocaine in rats.
- Overexpression of synaptogyrin-3 reduced cocaine self-administration and anxiety-like behaviors.
- Synaptogyrin-3 overexpression enhanced cognitive flexibility and nucleus accumbens dopamine signaling, mitigating cocaine-induced deficits.
Conclusions:
- Synaptogyrin-3 plays a significant role in the neurobiological adaptations associated with cocaine use disorder.
- Modulating synaptogyrin-3 levels presents a potential therapeutic strategy for treating cocaine addiction.
- Further research into synaptogyrin-3's mechanisms could lead to novel interventions for substance use disorders.
Related Concept Videos
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.0K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.0K
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
167
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
167
01:25Adrenergic Agonists: Indirect-Acting Agents
1.5K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.5K
01:29Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
01:26Neurochemical Transmission: Sites of Drug Action
2.2K
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
2.2K
01:15Drug Abuse and Addiction: Pharmacological Phenomena
448
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
448